We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ATRL:TSXAtkinsrealis Group Inc. Analysis

Data as of 2026-05-13 - not real-time

CA$88.90

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

AtkinsRéalis Group Inc. trades well below analyst target prices despite a P/E ratio that is a fraction of the industry average, indicating a substantial valuation gap. The stock benefits from a solid balance sheet, strong cash generation and a remarkably low dividend payout, suggesting dividend sustainability. Recent strategic acquisitions in Australia and the defence sector broaden the company’s geographic footprint and deepen its exposure to high‑growth infrastructure and power‑renewables markets. However, technical signals are mixed: the 20‑day SMA sits just above the current price, the MACD has turned bearish and volume is on a downtrend, pointing to short‑term pressure. The market sentiment index shows “Extreme Greed,” which may be inflating price momentum beyond fundamentals.
Overall, the fundamentals point to a resilient, cash‑rich business with attractive earnings yields, yet the current price appears stretched relative to discounted cash‑flow estimates, implying limited upside in the near term but potential upside if the valuation gap narrows over a longer horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and decreasing volume suggest limited upside
  • Price is near the identified support level
  • Acquisition announcements may be priced in already

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong cash flow and low payout ratio support earnings stability
  • Strategic acquisitions expand market presence in high‑growth regions
  • Valuation still above DCF fair value, limiting upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust ROE and operating margins indicate durable profitability
  • Diversified global footprint reduces reliance on any single market
  • Potential re‑rating as valuation gap narrows over time

Key Metrics & Analysis

Financial Health

Revenue Growth13.40%
Profit Margin23.89%
P/E Ratio5.8
ROE56.49%
ROA3.81%
Debt/Equity23.49
P/B Ratio2.7
Op. Cash FlowCA$461.3M
Free Cash FlowCA$477.4M
Industry P/E30.1

Technical Analysis

TrendNeutral
RSI41.3
SupportCA$87.41
ResistanceCA$98.24
MA 20CA$92.59
MA 50CA$92.11
MA 200CA$94.29
MACDBearish
VolumeDecreasing
Fear & Greed Index89.36

Valuation

Fair ValueCA$67.12
Target PriceCA$115.60
Upside/Downside30.03%
GradeOvervalued
TypeValue
Dividend Yield0.09%

Risk Assessment

Beta1.06
Volatility32.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.